v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities    
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ (3,405,000) $ (1,921,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock option compensation expense 699,000 615,000
Common stock issued for services 46,000 97,000
Credit loss expense 0 37,000
Amortization of debt discount 62,000 28,000
Amortization of right-of-use operating lease assets 49,000 27,000
Amortization of right-of-use finance lease asset 28,000 16,000
Operating lease liabilities (47,000) (25,000)
Finance lease liability (24,000) (21,000)
Gain on investment in South Korean joint venture 0 (2,000)
Depreciation expense 34,000 42,000
Changes in assets and liabilities:    
Accounts receivable (115,000) (1,077,000)
Inventories 18,000 (39,000)
Prepaid expenses and other assets 3,000 14,000
Deposits (1,000) 0
Contract liabilities 39,000 0
Net cash used in operating activities (2,917,000) (1,830,000)
Cash flows from investing activities    
Equipment purchases (32,000) 0
Net cash used in investing activities (32,000) 0
Cash flows from financing activities    
Proceeds from sale of common stock, net of offering costs 256,000 (15,000)
Common stock issued for financing fee 85,000 0
Repayment of debt obligations (8,000) (4,000)
Proceeds from Clyra Medical debt obligations 2,395,000 590,000
Net cash provided by financing activities 3,190,000 866,000
Net effect of foreign currency translation (2,000) (20,000)
Net change in cash 239,000 (984,000)
Cash and cash equivalents at beginning of period 3,883,000 3,548,000
Cash and cash equivalents at end of period 4,122,000 2,564,000
Supplemental disclosures of cash flow information    
Interest 126,000 37,000
Income taxes 0 0
Short-term lease payments not included in lease liabilities 13,000 12,000
Non-cash investing and financing activities    
Allocation of noncontrolling interest (641,000) (522,000)
Fair value of Clyra Medical warrants issued as debt discount 232,000 69,000
Clyra Medical dividend Series A Preferred stock 86,000 86,000
Clyra Medical Common Stock [Member]    
Cash flows from financing activities    
Proceeds from sale of common stock, net of offering costs 0 295,000
BioLargo Energy Technologies, Inc (BETI) [Member]    
Cash flows from financing activities    
Proceeds from BETI unit offering 462,000 0
Entities, Excluding Partially Owned Subsidiary [Member]    
Changes in assets and liabilities:    
Accounts payable and accrued expenses (135,000) 290,000
Accounts payable and accrued expenses (135,000) 290,000
Partially Owned Subsidiary [Member]    
Changes in assets and liabilities:    
Accounts payable and accrued expenses (168,000) 89,000
Accounts payable and accrued expenses $ (168,000) $ 89,000